Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.

David M Charytan,Marc S Sabatine,Terje R Pedersen,KyungAh Im,Jeong-Gun Park,Armando Lira Pineda,Scott M Wasserman,Prakash Deedwania,Anders G Olsson,Peter S Sever,Anthony C Keech,Robert P Giugliano

Journal of the American College of Cardiology（2019）

引用 113|浏览55

暂无评分

摘要

LDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633).

查看译文

关键词

atherosclerosis,cardiovascular disease,cardiovascular risk,chronic kidney disease,lipids,PCSK9

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要